Latest News and Press Releases

 ●Q1 Revenue of $11.5 million; a 13% increase year-over-year ●Q1 Cash Collections of $11.3 million; a 10% increase year-over-year to record levels ●Q1 Thyroid test volume up 16% year-over-year to...

 ●Q2 Revenue of $12.0 million; a $1.0M and 9% increase year-over-year ●Q2 Test volume up 12% year-over-year to record levels ●Q2 Cash collections of $11.0M; a $0.7M and 7% increase year-over-year ●Q2...

 ●Q1 Revenue of $10.3 million; a 4% increase year-over-year ●Q1 Test volume up 10% year over year to record levels PARSIPPANY, NJ, May 09, 2024 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc....

 ●Q4 and FY Revenue of $10.3 million and $40.2 million; a $8.4 million and 26% increase year-over-year ●Q4 and FY Income from Continuing Operations of $0.8 million and $1.1 million; a $7.0 million and...

 ●Q2 Revenue of $11.0 million; a 49% increase year-over-year; highest quarter in history ●Q2 Test volume up 15% year over year to record levels ●Q2 Reimbursement improvement up 34% year-over-year...

 ●Q1 Revenue of $9.8 million; a 24% increase year-over-year; highest quarter in history ●Q1 Test volume up nearly 20% year over year to record levels ●Q1 41.9 million covered lives added, resulting...

 ●Q4 Revenue of $8.3 million  ●Cash and Cash Equivalents total $4.8 million as of December 31, 2022 PARSIPPANY, NJ, March 27, 2023 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or...

Q3 Revenue of $8.2 million up 2% versus Prior YearQ3 Adjusted EBITDA PositiveCash and Cash Equivalents total $6.3 million as of September 30, 2022 PARSIPPANY, NJ, Nov. 14, 2022 (GLOBE NEWSWIRE)...

 ●Q2 Revenue of $9.4 million down 16% versus Prior Year driven by an unexpected retroactive price decrease on ThyGeNEXT® ●2022 Year to Date Net Loss Improves by $1.5 million ●Days Sales Outstanding...